{"pub": "dailymail", "url": "https://thisismoney.co.uk/money/markets/article-7615077/MARKET-REPORT-Turnaround-hopes-send-WPP-Footsie.html", "downloaded_at": "2019-10-26 00:22:13.457575+00:00", "title": "MARKET REPORT: Turnaround hopes send WPP to the top of the Footsie", "language": "en", "text": "WPP barrelled to the top of the Footsie leaderboard after it clocked its first quarterly revenue growth in more than a year.\n\nThe update was a pleasant surprise from the world\u2019s biggest advertising company.\n\nIt posted a 0.7 per cent rise in sales growth between July and September, far surpassing analysts\u2019 estimates of minus 0.6 per cent.\n\nThe firm has been fire-fighting a lacklustre performance, lagging share price and management turmoil after former boss Sir Martin Sorrell abruptly left last year.\n\nTurning point: WPP boss Mark Read, who replaced Sir Martin Sorrell last year, hailed the advertising firm's first quarterly revenue growth in more than a year\n\nBut replacement Mark Read hailed the turnaround yesterday, in a set of figures Societe Generale analysts dubbed \u2018pivotal\u2019.\n\nLiberum brokers noted that the firm didn\u2019t raise full-year guidance, in a move they said \u2018could raise questions\u2019, but this was attributed to the company taking a cautious stance on its rebound.\n\nWPP shares were 6.1 per cent higher, up 56p, to 974.4p by the close.\n\nIn a bleaker trading update, chemicals group Synthomer issued a profit warning and said it is reviewing its assets between now and next March, when it will release annual results.\n\nThe FTSE 250-listed group believes 2019 profit before tax will be 10 per cent lower than in 2018, when it made \u00a3135million.\n\nStock Watch - Cambridge Cognition Cambridge Cognition could benefit from two companies\u2019 renewed efforts to get an Alzheimer\u2019s drug approved by US regulators. The AIM-quoted firm believes its Cantab Mobile memory test could be needed by Biogen and Eisai to identify patients if the US Food and Drug Administration signs off on their aducanumab treatment in early 2020. The test is carried out on an iPad and assesses for cognitive decline and depression. Shares rose 9.8 per cent, or 2.5p, at 28p.\n\nIt said this had mostly been driven by \u2018increased weakness\u2019 in a division that makes rubber products which can be used to make items from tyres and shoe heels to chewing gum.\n\nLike many companies that have recently warned on their performance, it also blamed \u2018depressed European industrial activity combined with increased political and economic uncertainties\u2019.\n\nShares tumbled 9.4 per cent, or 29p, to 280.6p. Synthomer\u2019s drop helped push the FTSE 250 0.2 per cent lower, or 48.64 points, to 20103.51.\n\nThe FTSE 100 snapped a four-day winning streak as traders worried that the US-China trade spat was heating back up after US vice president Mike Pence accused China of curtailing \u2018rights and liberties\u2019 in Hong Kong in a controversial speech on Thursday.\n\nLondon\u2019s premier index fell only slightly by 0.05 per cent, or 3.78 points, to 7,324.47, seemingly unmoved by news that the EU had agreed to extend the deadline for Brexit.\n\nBP investors were nonplussed by its \u00a33.9million investment in a tree-planting firm, with shares shedding 0.4 per cent, or 2p, to close at 512p.\n\nThe energy group\u2019s venture capital arm has pumped the money into Finite Carbon, a forestry group that manages more than 40 projects across 3m acres, in its latest bid to boost its green image.\n\nBP reports third-quarter figures next Tuesday.\n\nA mixed set of production results from mining and commodities trader Glencore sent shares 0.8 per cent, or 1.9p, higher by the close, to 234.25p.\n\nCopper output fell 4 per cent and gold by 20 per cent, while cobalt rose by 21 per cent and coal by 8 per cent.\n\nThe Switzerland-based group lowered its full-year production guidance for copper, ferrochrome and zinc.\n\nFellow blue-chip miner BHP rose by 0.7 per cent, or 12.2p, to 1657.2p after analysts at RBC Capital Markets upgraded its rating to \u2018outperform\u2019 from \u2018sector perform\u2019.\n\nMorrisons lost ground after it revealed fund manager Silchester International Investors doubled its stake in the firm from 5 per cent to 10 per cent. Morrisons shares shed 1.8 per cent, or 3.6p, to 201.1p.\n\nBut small-cap gold miner Petropavlovsk, on the other hand, added 2.6 per cent, or 0.25p, to close at 9.77p after it revealed Russian businessman Vladislav Sviblov had taken a 4.6 per cent stake in the firm.\n\nOver on AIM, insolvency specialist Begbies Traynor rallied 2.9 per cent, or 2.5p, to 87.5p, after it bought a smaller rival, London-based Alexander Lawson Jacobs, for at least \u00a32.4million.", "description": "The world's biggest advertising company posted a 0.7 per cent rise in sales growth. Boss Mark Read hailed the turnaround, in a set of figures Societe Generale analysts dubbed 'pivotal'.", "authors": ["Francesca Washtell For The Daily Mail", "Some Links In This Article May Be Affiliate Links. If You Click On Them We May Earn A Small Commission. That Helps Us Fund This Is Money", "Keep It Free To Use. We Do Not Write Articles To Promote Products. We Do Not Allow Any Commercial Relationship To Affect Our Editorial Independence."], "top_image": "https://i.dailymail.co.uk/1s/2019/10/25/21/20196766-0-image-a-15_1572034417555.jpg", "published_at": "2019-10-25"}